Additionally, recent research has introduced a bimodal biosensor that employs a dual CRISPR-Cas12a system to quantify targets via fluorescence and electrochemical signals, explicitly targeting the epidermal growth factor receptor (EGFR) mutation L858R in specific non-small cell lung cancer (NSCLC) patients. Here, EGFR is linked to non-small cell lung carcinoma.